Articles
Rapid Isolation of Monoclonal Antibody Producing Cell Lines
March 27, 2009
•Feature Article: Rapid Isolation of Monoclonal Antibody Producing Cell Lines
By Julian F. Burke and Chris J. Mann
With reports suggesting a compound annual growth rate for monoclonal antibodies (MAbs) of 43%, a predicted rise of biopharmaceutical products is driving the development of systems for isolating the best producers among genetically engineered cell lines (1). Isolation of a high-producing cell line can decrease the time it takes to get to a phase 1 clinical trial and ultimately lower the cost of large-scale production.
Assuming that 3 kg of a product is required for phase 1 and 2 trials and that the yield after purification is 60%, it has been suggested that the number of runs for a 1000-L batchfed reactor can vary from 10 for a cell line producing 0.5 g/L to a single run for a cell line producing what is probably the current limit of 5 g/L (2).
Reprinted with permission from BioProcess International 4(5):S48-S51 (May 2006)
Click Here To Download:•Feature Article: Rapid Isolation of Monoclonal Antibody Producing Cell Lines
